Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach targets liver tumors without surgery

NCT ID NCT03408665

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SBRT (stereotactic body radiation therapy)
What this could lead to
If successful, this could provide a non-invasive treatment option to control liver tumors and delay progression.
What could go wrong
This is a phase II study, so results are preliminary. The treatment may not improve survival or could cause side effects like liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

280 people

The number who actually took part.

Started

Mar 2019

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * With primary or secondary liver tumor and matching one of the following situations: * Liver Metastasis (LM): anatomopathologic diagnosis of the primary tumor * Hepatocellular Carcinoma (HCC): diagnosis achieved through biopsy or through non-invasive methods approved by AASLD criteria (Bruix, 2011) * Cholangiocarcinoma (CC): diagnosis achieved through biopsy * Other primitive hepatic tumor achieved through biopsy * Meet the requirements for SBRT treatment: * Liver Metastasis (LM): oligometastatic disease * Hepatocellular Carcinoma (HCC): non eligible lesion to curative surgery * Cholangiocarcinoma (CC): nodular lesion * Other primitive hepatic tumor: non eligible lesion to curative surgery * Able to receive a SBRT treatment according to the multidisciplinary consultation meeting * Tumor assessable with CT-scan or MRI according to mRECIST in HCC or Recist 1.1 in other situations * Affiliation to the National Social Security System * With informed and signed consent Exclusion Criteria: * Eligibility to a curative surgery according to the multidisciplinary consultation meeting * Contraindication to SBRT (especially Cirrhose Child C) * Pregnant or breastfeeding women * Patient Under guardianship or tutorship * Impossibility to submit at the study procedures due to geographic, social or mental reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma hepatocellular carcinoma liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer Liver metastases

Contacts and locations

Locations

  • Centre Léonard de Vinci

    Dechy, France

  • Centre Oscar Lambret

    Lille, Nord, 59020, France

  • Centre Paul Strauss

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, 94800, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, France

  • Institut de Cancérologie Paris Nord

    Sarcelles, 95200, France

  • Institut de Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, 54519, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.